Κατεύθυνση Επεμβατική Ακτινολογία
Library of the School of Health Sciences

2014-07-08

2014

Παπαλουκά Βασιλική

Νικόλαος Κελέκης Καθηγητής, Αλέξιος Κελέκης Επίκουρος Καθηγητής, Δημήτριος Φιλιππιάδης

Διαδερμικός θερμοκαυτηριασμός πρωτοπαθών και δευτεροπαθών αλλοιώσεων με μικροκύματα.

Greek

Subcutaneus microwave thermoablation of primary and secondary lesions

New technologies for microwave ablation (MWA) have been designed, aiming to
minimize the limitations of this modality and to achieve larger areas of
coagulation necrosis, compared with currently available MWA devices. The aim of
this retrospective study is to evaluate the safety and to determine technical
and clinical efficacy of CT - guided MW ablation (140W continuous wave at
2450MHz) in patients with primary or secondary malignant lesions. In a period
of 20 months, 35 patients (27/8 male/female) underwent CT-MWA under computed
tomography guidance. Lesions included focal liver lesions (28): Hepatocellular
Carcinoma (16), Cholangiocarcinoma (1) and liver metastases (11) [7 colorectal/
3 lung cancer/ 1 ocular melanoma], Renal Cell Carcinoma (3) and osseous
metastasis with soft tissue mass (4). Mean diameter of the tumor was 2.9±1.5
cm. Each session lasted 5 -10 minutes using a power raging between 40- 140W.
Follow-up contrast enhanced CT scans was obtained immediate post the session
and a Gd-DTPA-enhanced MRI was performed at 1st, 3rd, 6th and 12th month after
treatment and every 6 months afterwards. Follow-up imaging revealed: total
necrosis in 31/35 (88.6%) patients and tumor remnant in 4/35 (11.4%) patients
who underwent a second session (3/4) and even a third session (1/4). No deaths
or major complications were reported. Minor complications including
insignificant subcapsular liver hematoma (1 patient) and a small pneumothorax
(2 patients with lesion located in hepatic dome). CT-MWA using a high energy
delivering system (up to 140W continuous wave at 2450MHz) is a safe and
effective alternative to already existing microwave systems with comparable
potential complication rates. Randomized, comparable clinical studies are
necessary for confirmation.

Thermoablation, Microwave, CT- guided , Subcutaneus ablation, Primary and secondary tumor

No

0

Yes

193

136

File access is restricted only to the intranet of UoA.

https://pergamos.lib.uoa.gr/uoa/dl/object/1310526